ArticleCancer immunology, immunotherapy : CII2024

Long-term survival after anti-PD-1 discontinuation in advanced cutaneous squamous cell carcinoma (cSCC): a proof of concept of benefit of concomitant cemiplimab and radiotherapy.

Barbara Bailly-Caillé et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.